2.64
+0.11(+4.35%)
Currency In USD
Address
1201 Orange Street
Wilmington, DE 19801
United States of America
Phone
484 254 6134
Website
Sector
Healthcare
Industry
Biotechnology
Employees
2
First IPO Date
December 04, 2017
| Name | Title | Pay | Year Born |
| Mr. Matthew Patrick Duffy | Chief Business Officer & Co-Chief Executive Officer of Hope Therapeutics | 338,000 | 1963 |
| Dr. Jonathan C. Javitt M.D., M.P.H. | Co-Founder, Chief Scientist Officer, Chairman & Interim Chief Executive Officer | 825,000 | 1957 |
| Dr. Riccardo Panicucci Ph.D. | Chief Manufacturing & Technology Officer | 240,000 | 1961 |
| Dr. Philip T. Lavin Ph.D. | Chief Methodologist | 0 | 1947 |
| Suzanne Messere | Investor Relations | 0 | N/A |
| Mr. Michael S. Abrams | Chief Financial Officer | 0 | 1970 |
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.